HY 2023 Results

UCB Now at Inflection Point

Our Purpose:
Create value for patients, now and into the future

Capital Market Earnings Call
27 July 2023
Disclaimer & Safe harbor

This presentation contains forward-looking statements, including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation.

Important factors that could result in such differences include but are not limited to: the global spread and impact of pandemics (such as COVID-19), wars on territories where UCB has businesses, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems. Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this presentation, and do not reflect any potential impacts from the evolving COVID-19 pandemic, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of this pandemic to UCB.

UCB expressly disclaims any obligation to update any forward-looking statements in this presentation, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereeto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

In the event of any differences between this Presentation and the Annual or Half Year Report, the information included in the Report shall prevail.

UCB - HY results 2023, July 2023
01 Jean-Christophe Tellier – CEO
OVERVIEW
UCB now at inflection point – ready to start a new phase of growth

02 Sandrine Dufour – CFO
2023 HY PERFORMANCE
Financially healthy first 6 months 2023 – prepared for growth
Guidance for 2023 confirmed

03 Jean-Christophe Tellier – CEO
CONCLUSION
We have strong growth ahead…
UCB now at inflection point – ready to start a new phase of growth

Jean-Christophe Tellier
CEO
# 2023 HY Performance | At-a-Glance

## Reaching the inflection point & investing behind ongoing and upcoming launches – growth ahead

<table>
<thead>
<tr>
<th>Revenue</th>
<th>Underlying profitability (adjusted EBITDA)</th>
<th>Net sales: € 2.4 bn (-12%; -14% CER)</th>
</tr>
</thead>
<tbody>
<tr>
<td>€ 2.6 bn (-11%; -13% CER)</td>
<td>€ 801 M (-2%; -9% CER)</td>
<td>or 31% of revenue</td>
</tr>
</tbody>
</table>

## HY 2023 marked by...

- **CIMZIA®** positive growth,
- **FINTEPLA®**, **EVENITY®** and **BIMZELX®** launches,
- **VIMPAT®** LOE performance as anticipated
- Underlying net sales growth (adjusted for **VIMPAT®**) of plus 8%;
- strong volume growth across the portfolio
- Ongoing launch investments, **Zogenix** becoming earnings accretive
- bimekizumab delay in the U.S.

## Clinical pipeline delivering

- **4 approvals & launches**: **FINTEPLA®** / LGS in EU, **BIMZELX®** / PsA & axSpA in EU, **RYSTIGGO®** / gMG in U.S.
- **10 filings under review** in U.S., EU and Japan (PSO, gMG, PsA, AS, axSpA & HS)
- **7 submissions under preparation for U.S., EU and Japan** (PsA, AS, axSpA, HS, focal epilepsy & LGS)

All 11 clinical pipeline projects with news flow in 2024

## Guidance 2023 confirmed

- Revenue expected: **€ 5.15 - 5.35 bn**
- adj. EBITDA: **22.5% - 23.5%**

---

gMG: generalized myasthenia gravis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; (nr-)axSpA: (non-radiographic) axial spondyloarthritis; HS: hidradenitis suppurativa; LGS: Lennox-Gastaut syndrome; CER: Constant Exchange Rates; LOE: Loss of Exclusivity;

UCB - HY results 2023, July 2023
## HY 2023 - 4 approvals & launches and 3 filings – more to come

Ongoing regulatory reviews = expected approvals, followed by launches

### 2023 approvals and ongoing regulatory reviews

**FINTEPLA® / LGS**
- EU

**RYSTIGGO® / gMG**
- U.S.

**BIMZELX® / PsA**
- EU

**BIMZELX® / axSpA**
- EU

- zilucoplan / gMG
  - Japan

- rozanolixizumab /gMG
  - Japan

- bimekizumab / PsA
  - Japan

- bimekizumab nr-axSpA / AS
  - Japan

- bimekizumab / PSO
  - U.S.

- zilucoplan / gMG
  - U.S.

- bimekizumab / HS
  - EU

### 2023 filings...

- rozanolixizumab / gMG
  - Japan

- bimekizumab / HS
  - EU

- fenfluramine / LGS
  - Japan

- bimekizumab / AS / HS
  - U.S.

- brivaracetam
  - Japan

- bimekizumab / HS
  - Japan

### Q1 2023
- **Q2 2023**
- **Q3 2023**
- **Q4 2023**

### H1 2024
- 11 clinical study read-outs across UCB clinical pipeline in 2024

### H2 2024
- rozanolixizumab / gMG
  - EU

- bimekizumab / HS
  - EU

---

gMG: generalized myasthenia gravis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; (nr-)axSpA: (non-radiographic) axial spondyloarthritis; HS: hidradenitis suppurativa; LGS: Lennox-Gastaut syndrome; CHMP: Committee for Medicinal Products for Human Use; EU: Europe; GB: Great Britain

UCB - HY results 2023, July 2023
Leading Epilepsy Portfolio Reached Inflection Point with 3 Growth Drivers

2023 HY Net Sales
€ 2,378 M¹
(-12%; -14% CER)

Epilepsy
€ 957 M
(-33%; -32% CER)

---

<table>
<thead>
<tr>
<th>Product</th>
<th>€ M</th>
<th>ACT</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td>KEPPRA®</td>
<td>€ 336</td>
<td>-12%</td>
<td>-9%</td>
</tr>
<tr>
<td>BRIVIACT®</td>
<td>€ 273</td>
<td>+21%</td>
<td>+20%</td>
</tr>
<tr>
<td>VIMPAT®</td>
<td>€ 204</td>
<td>-73%</td>
<td>-72%</td>
</tr>
<tr>
<td>FINTEPLA®</td>
<td>€ 102</td>
<td>&gt;100%</td>
<td>&gt;100%</td>
</tr>
<tr>
<td>NAYZILAM®</td>
<td>€ 42</td>
<td>+17%</td>
<td>+16%</td>
</tr>
</tbody>
</table>

Generic erosion in Japan since January 2022 is now slowing down, important epilepsy drug in many regions for millions of patients.

Significant continued strong growth in all regions.

Since March 2022 – new treatment option for patients and families living with Dravet and LGS, rare epilepsy syndromes that are particularly challenging to treat.

Reaching more and more patients.

---

¹Net sales include € 18 M designated hedges reclassified to net sales; Before this reclassification: Net sales -15%

ACT = Actual; CER = constant exchange rates; EB = Established Brands; LGS = Lennox-Gastaut Syndrome

UCB - HY results 2023, July 2023
UCB in generalized Myasthenia Gravis – Elevate Standard of Care and Maximize Patient Outcomes

**gMG adult patient population**

- **120k patients** by 2032
- **112k patients** could benefit from targeted therapies upon expansion into earlier lines (2023)
- **56k patients** represent those with the highest unmet need (2023)

### UCB gMG Portfolio – 2 different targeted therapies

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ZILUCOPLAN</strong></td>
<td>Complement C5 inhibitor</td>
</tr>
<tr>
<td><strong>RYSTITIGO</strong></td>
<td>Anti-FcRn antibody</td>
</tr>
</tbody>
</table>

First and only FDA approved FcRn indicated to treat the broadest gMG patient population – AChR Ab+ and MuSK+ gMG, addressing ~95% of gMG patients.

When approved: The only at home self-administration targeted therapy to inhibit the complement cascade at 2 distinct points providing complete complement inhibition.

---

AChR Ab+, positive for autoantibodies against acetylcholine receptors; gMG, generalised myasthenia gravis; HCP, healthcare professional; IVIg, intravenous immunoglobulin; MuSK Ab+, positive for autoantibodies against muscle-specific kinase; PLEX, plasma exchange; RLZ, rozanolixizumab; ** patient numbers in G7

UCB - HY results 2023, July 2023
Commercial Execution in Immunology – 3 Growth Drivers

2023 HY Net Sales
€ 2 378 M
(-12%; -14% CER)

Immunology
€ 1 093 M
(+8%; +8% CER)

<table>
<thead>
<tr>
<th>Drug</th>
<th>€ M</th>
<th>ACT</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIMZIA®</td>
<td>€ 1 017</td>
<td>+2%</td>
<td>+2%</td>
</tr>
<tr>
<td>BIMZELX®</td>
<td>€ 52</td>
<td>&gt;100%</td>
<td>&gt;100%</td>
</tr>
<tr>
<td>EVENITY®</td>
<td>€ 24</td>
<td>&gt;100%</td>
<td>&gt;100%</td>
</tr>
</tbody>
</table>

- Gaining market share in the anti-TNF market based on differentiation
- Patients are growing in all regions, Volume +8%
- Strong access expansion and launch momentum now captures more than one third of new and switch prescriptions of IL-17 products for psoriasis, review in US ongoing
- Successful launches in Europe, a leader in bone builder market
  "other operating income": Net contribution from Amgen +44%

Net sales outside Europe reported by Amgen 3-AUG23

ACT = Actual; CER = constant exchange rates; EB = Established Brands
1Net sales include € 18 M designated hedges reclassified to net sales; Before this reclassification: Net sales -15%

UCB - HY results 2023, July 2023
Establishing Bone Builder Leadership with EVENITY®
Leading in U.S., Japan, South Korea, Australia, Canada, Belgium

Worldwide

Reach

> 485 k patients at high risk of fracture reached since launch

Europe

Market Share

Trending above 30% patient share per country 2yrs after launch

Net Sales

€ 24 M sales in Europe in H1 2023

Amgen reports ex-EU sales 3-AUG23

Net Contribution from Amgen EVENITY® to UCB’s P&L

1 as of April 30th, 2023
Patient share based on data from IQVIA on the bone builder market as of 31st of December 2022: EVENITY®, Forteo, teriparatide biosimilars / generics + Teribone (Japan) + Tymlos (U.S.). (normalized to “Days of Therapy”)

UCB - HY results 2023, July 2023
BIMZELX® IL-17 Dynamic Leadership Leads to Sustained Patient Uptake

Estimated cumulative monthly treated patients
EU – JPN – CAN

IL-17 Dynamic Shares

≥35%

at the end of June 2023

Approved for PsA and axSpA in EU in JUN23

Under review for PsA, nr-axSpA and AS in Japan

Under review for HS in EU

Under review for PSO in U.S.

1Estimated treated patients derived from volume in Europe; Canada source: Patients on Drug via Canada PSP (Bayshore); Inclusive of Bridging (Public + Private) and Commercial; Japan source: IQVIA In-market data - ETP Japan; Volume from analogues based on IQVIA Midas. UCB independent analysis of data to show adequate comparisons across different dosing schedules.

PsA: psoriatic arthritis; AS: ankylosing spondylitis; (nr-)axSpA: (non-radiographic) axial spondyloarthritis; HS: hidradenitis suppurativa;

UCB - HY results 2023, July 2023

Dynamic Share: Market share among switch and new patients
Source: IQVIA, UCB calculations based on internal and external sources
2023 HY Performance

Financially healthy first 6 months 2023 – prepared for growth
Guidance for 2023 confirmed

Sandrine Dufour
CFO
HY 2023 | Reaching the Inflection Point
Ready for growth thanks to focused resource allocation and investments behind multiple launches

Leaving loss of exclusivity impacts behind us

- Underlying net sales growth of plus 8% in the first six months (adjusted for VIMPAT®)

Strong cost discipline: Enabling company growth

- “Focus-for-Growth”
  - Transversal program driving sustainable efficiency and allowing value-based resource allocation
- First positive result in 2022 and full deployment in 2023
- Absorption of inflation costs
- Focused reallocation of marketing and selling resources behind ongoing and expected launches

Zogenix becoming earnings accretive

- As guided in 2022

The second half of the year is planned to be marked by significant investments behind the ongoing and upcoming launches.
## 2023 HY Financial Highlights

**Inflection point towards growth and investment behind multiple launches**

<table>
<thead>
<tr>
<th>Revenue</th>
<th>HY 2023</th>
<th>Actual</th>
<th>CER</th>
</tr>
</thead>
</table>
| Net Sales € 2 378 M (-12%; -14% CER)  
Good portfolio growth compensated by LOE impacts VIMPAT® and E KEPPRA®  
underlying net sales growth - adjusted for VIMPAT® - +8% | € 2 589 M | -11% | -13% |
| Adjusted Gross Profit | € 2 004 M | -11% | -13% |
| Total Operating Expense € 1 302 M (-15%; -14% CER) |  |
| In-line with topline performance  
Gross margin before amortization of intangible assets linked to sales: stable at 77% | € 1 302 M | -15% | -14% |

<table>
<thead>
<tr>
<th>Total Operating Expense</th>
<th>HY 2023</th>
<th>Actual</th>
<th>CER</th>
</tr>
</thead>
</table>
| Marketing and selling expenses:  
Global launch activities, preparation for potential upcoming launches | € 753 M | +3% | +4% |
| R&D expenses:  
Late-stage pipeline with 5 phase 3 and 4 phase 2 assets – Ratio 29% after 27% | € 759 M | -5% | -4% |
| General and admin. expenses:  
improved value-focused allocation of resources, ceasing integration costs for Zogenix | € 104 M | -9% | -9% |
| Other operating income: € 156 M net contribution (+44%) from Amgen for EVENITY®, € 145 million from the sale of a portfolio of established brands in Europe | € 315 M | >100% | >100% |

| Adjusted EBITDA* | € 801 M | -2% | -9% |

<table>
<thead>
<tr>
<th>Profit</th>
<th>HY 2023</th>
<th>Actual</th>
<th>CER</th>
</tr>
</thead>
</table>
| Lower restructuring and other expenses (€ 6 M after € 61 M in June 2022),  
Tax Rate 22% | € 311 M | -22% | -33% |

| Core Earnings per Share | € 2.63 | -16% | -27% |

**Adjusted EBITDA**

Adjusted EBITDA / revenue ratio 31% after 28% in June 2022

**Profit**

Lower restructuring and other expenses (€ 6 M after € 61 M in June 2022),  
Tax Rate 22%

**Core Earnings per Share**

Based on 189 M weighted average shares outstanding**  
(June 2022: 190 M)

---

CER = Constant Exchange Rates  
*Earnings before Interest Taxes Depreciation & Amortization. **Total number of shares 194.5 M.  
UCB - HY results 2023, July 2023
Financial Guidance for 2023 – Confirmed
Ready for growth, investing behind multiple launches, Zogenix acquisition becoming earnings accretive

<table>
<thead>
<tr>
<th>Revenue expected</th>
<th>€ 5.15 - 5.35 bn</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Robust product portfolio</td>
<td></td>
</tr>
<tr>
<td>• FINTEPLA®</td>
<td></td>
</tr>
<tr>
<td>• Expected launches bimekizumab, rozanolixumab and zilucoplan</td>
<td></td>
</tr>
<tr>
<td>• Loss of exclusivity annualized for VIMPAT®</td>
<td></td>
</tr>
</tbody>
</table>

Adjusted EBITDA*/revenue margin expected 22.5 - 23.5%

• Continued investments into launches
• Zogenix earnings accretive

Core EPS € 3.40 - 3.80**

• Tax rate expected "around 20%"

Peek sales guidance

- ≥ € 2 bn achieved in 2022
- ≥ € 600 M by 2024
- ≥ € 800 M by 2026
- ≥ € 800 M by 2027

Financial guidance for 2025 is unchanged

*Earnings before Interest Taxes Depreciation and Amortization, **Based on 190 M shares outstanding
UCB - HY results 2023, July 2023
We have strong growth ahead...

...creating value for all stakeholders, now and into the future

Jean-Christophe Tellier
CEO
INFLECTION POINT
Reached

CREATING
Value for all stakeholders, now and into the future

BRINGING
• New treatment options for people living with severe diseases
• Growth and healthy profitability on a sustainable basis

DELIVERING
• Approvals and submissions
• Multiple new launches

MANAGING
• LOE erosions
• Delay of bimekizumab U.S. launch

Inspired by patients. Driven by science.
UCB - HY results 2023, July 2023
Thank you... your questions, please
Inspired by patients.
Driven by science.